Physician profile
Michael J Septer
NPI 1013908060
$14,510.47
in general payments reported to CMS, 2019-2025
57 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $1,466 · 2021: $2,853 · 2022: $2,344 · 2023: $2,314 · 2024: $2,365 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,295 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,295.21 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,245.75 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,286.29 | 2020-2025 | Caplyta |
| Glaxosmithkline, LLC. | $1,119.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,020.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $1,019.18 | 2019-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $925.78 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $891.93 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $658.49 | 2019-2025 | Qelbree, Qelbree, Xyosted |
| Pfizer INC. | $572.13 | 2019-2024 | |
| Lilly USA, LLC | $484.24 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Allergan, INC. | $470.41 | 2019-2021 | |
| Lundbeck LLC | $460.94 | 2020-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $383.82 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $297.20 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $248.67 | 2024-2025 | Fanapt, Hetlioz |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Septer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.